Abstract:Objective:To evaluate the efficacy and safety of Moxifloxacin vs levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease(uPID) in China.Methods:Prospective,randomised,double-blind,double-dummy,parallel-group study.Setting:Multicentre,multinational study in the inpatient and/or outpatient setting.Population:Women(aged ≥ 18 years) with uPID(defined as PID with no pelvic or tubo-ovarian abscess on pelvic ultrasonography and/or at laparoscopic examination) and not requiring intravenous treatment.Women received a 14day course of either oral Moxifloxacin,400mg once daily,or oral levofloxacin,500mg once daily,plus oral metronidazole,500mg twice daily.The primary measure of efficacy was clinical response at test of cure(TOC)(7~14 days after the last dose of study drug) in the per-protocol population(PP).Other measures were clinical response during therapy and at 4-week follow-up,microbiological response at TOC,and safety.Results:A total of 306 subjects were randomized,including 151 cases in Moxifloxacin group and 155 cases in Levofloxacin plus Metronidazole group.For the primary measure of efficacy(clinical cure at TOC),Moxifloxacin was non-inferior to levofloxacin plus metronidazole(79.7% and 79.7% in Moxifloxacin group and Levofloxacin plus Metronidazole group respectively,P=0.9823).Bacteriological success rates were high and comparable between treatment arms(In the PP population,bacterial clearance rates at TOC visit in MBV subjects was 84.2% and 81.3% in Moxifloxacin group and Levofloxacin plus Metronidazole group respectively,P=0.9227)).For the second measure of efficacy(clinical cure at TOC),Moxifloxacin was non-inferior to levofloxacin plus metronidazole(79.7% and 79.7% in Moxifloxacin group and Levofloxacin plus Metronidazole group respectively,P=0.9931).Success rates were high and comparable between treatment arms(In the PP population,bacterial clearance rates at TOC visit in MBV subjects was 68.4% and 81.3% in Moxifloxacin group and Levofloxacin plus Metronidazole group respectively,P=0.4078).Conclusion:Moxifloxacin monotherapy,400 mg once daily for 14 days,is an effective and well-tolerated oral treatment for women with uPID.

Clinical efficacy of ofloxacin and levofloxacin treatment on pelvic inflammatory disease

Study on the efficacy and safety in uncomplicated pelvic inflammatory disease

Clinical effect of Hongteng decoction combined with levofloxacin in the treatment of chronic pelvic inflammatory disease and its effect on inflammatory factors

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Clinical efficacy of Pudilanxiaoyankoufuye in treatment of chronic pelvic inflammation

The clinical efficacy and safety evaluation of cefazolin sodium combined with levofloxacin for acute urinary tract infection

Effect of mercifloxacin and levofloxacin on urinary tract infection

Clinical evaluation of levofloxacin sequential therapy in the treatment of 214 patients with bacterial infections

[Multicenter Randomized Controlled Clinical Study on Levornidazole and Sodium Chloride Injection in the Treatment of Pelvic Anaerobic Infections].

Observation on clinical effects of intravenous levofloxacin 500 mg once-daily vs 300 mg twice-daily in the treatment of lower respiratory tract bacterial infections

A multicenter double-blind randomized controlled clinical study of parenteral gatifloxacin versus levofloxacin in the treatment of acute lower respiratory tract infections

The comparison of clinical efficacies of pazufloxacin and levofloxacin hydrochloride injection in treatment of respiratory infection and urinary infection

Safety and Efficacy of Levofloxacin Versus Ciprofloxacin for the Treatment of Chronic Bacterial Prostatitis in Chinese Patients

Clinical study of lomefloxacin compared with ofloxacin in the treatment of bacterial infections

A retrospective study of the efficacy and safety of levofloxacin in children with severe infection

Meta-analysis of High-dose and Routine-dose of Levofloxacin in the Treatment of Respiratory Tract Infection

On Safety and Pharmacoeconomics of Moxifloxacin in the Management of Urinogenital Infection

Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis

Randomized Controlled Study on Gatifloxacin and Levofloxacin Injection in the Treatment of Acute Gonococcal Urinary and Reproductive Tract Infections

Curative Effect Observation on Comprehensive Treatment for Pelvic Inflammatory Disease

A Randomized Controlled Clinical Study on Levofloxacin Versus Ciprofloxacin in the Treatment of Bacterial Infections